Near-tetraploid acute myeloid leukemias (NT-AML) constitute an unusual presentation defined by blasts containing 80-104 chromosomes without aberrant near-diploid metaphases. Only about 60 NT-AML cases have been described so far in the literature. 1 Reported cases where detailed information was available can be classified as M2 AML with duplication of t(8;21)(q22;q22) (N ¼ 13), 1,2 acute promyelocytic leukemias (M3 AML) with duplication of t(15;17)(q22;q21) (N ¼ 4)
1,3 -both categories reported mostly from Asian patients -or acute erythroleukemias M6 AML (N ¼ 7)
1 and M0-M5 AML putatively originating from pluripotent myeloid progenitors characterized by erythroblastic and/or megakaryocytic (EM) dysplasia (N ¼ 17). 4 Near-tetraploid blast cells are characterized by their large size on bone marrow smears, [2] [3] [4] but individual chromosomal abnormalities are often difficult to analyze because of their 'fuzzy appearance'. 1, 4 In order to collect more information on these rarely occurring AML, immunophenotypic and clinical databases of members of the EGIL group were searched to identify morphologically and immunophenotypically well-defined NT-AML patients. As this study was not initiated from comprehensive cytogenetic databases, the results do not provide any indication on the incidence of NT-AML. However, it allowed to retrospectively retrieve information on 25 cases of NT-AML, diagnosed between 1989 and 2003 in eight European countries. 4, 5 This group of NT-AML comprised nine females and 16 males with a median age of 64 years (range 19-81 years) ( Table 1) . Seventeen patients presented with de novo NT-AML but two of them (no. 7 and 8) had a history of treatment with immunosuppressive drugs (steroids, cyclosporine A or methotrexate) for 3-5 years. Two patients had therapy-related AML (t-AML), six had antecedents of myelodysplastic syndrome (MDS). Smears of 21/ 25 patients were reevaluated by one of the authors (PL). WHO criteria identified 14 AML with multilineage and 11 with singlelineage dysplasia AML. Yet, in 10 of the latter cases, this involved a different lineage than that of the leukemic blasts, suggesting multilineage involvement. The group of eight patients with secondary NT-AML, 63-to 81-year-old, was significantly older (P ¼ 0.039) than that of de novo ones. M6 and M7 NT-AML also manifested multiple myeloid lineage involvement but are considered separately because of different characteristics of their diseases (Tables 1-4) .
Peripheral blood cell analyses in the 21 patients with M0-M5 NT-AML showed frequent (90% of patients) anemia (median Hb 81 g/l) and thrombocytopenia (median 83 G/L). There was leucopenia in 52% of the patients and leukocytosis in 33%. Peripheral blood involvement, with blasts between 5 and 95%, was seen in 18 patients. Bone marrow aspirates showed infiltration by 45-95% blasts (median 84), with 5-95% neartetraploid blasts (median 62), and 0.4-39% erythroblasts (median 10, Table 1 ).
Cytochemical and morphological examinations established the diagnosis of AML as 3 M1, 1 M2, 3 M4, 3 M5a, 3 M6, whereas immunophenotyping evidenced 10 M0 (40%), 1 M7 (CD41 þ and CD61 þ ) and 1 NOS (Tables 1 and 2 ). (Table 3) . Normal metaphases were found in 18 patients. At least one marker chromosome was observed in 10 cases. Using fluorescence in situ hybridization (FISH) or high-resolution (HR) techniques in 14 cases, karyotypic abnormalities typical for AML with a complex aberrant karyotype were observed, such as structural and/or numerical abnormalities of chromosome 5 in eight patients, of chromosome 7 in eight, and changes of both chromosomes in six. Karyotypic abnormalities involving chromosome 1 were found in four patients, chromosome 2 in six, and chromosome 3 in four. In six patients, there was a deletion of chromosome 17 or of part of it. Chromosomal translocations characteristic of AML with recurrent genetic abnormalities 6 were not found in any case. This was confirmed by the negative results of molecular analysis for PML/RARa in two patients, AML1/ETO in five, and CBFb/MYH11 in three. The BCR/ABL rearrangement was also negative in all eight cases examined.
Intensive chemotherapy based on anthracycline with standard (A), intermediate (id-A) or high doses (hd-A) of cytosine arabinoside, supplemented with etoposide in five patients or 6-thioguanine in three, induced complete remission (CR) in eight of 16 (50%) patients with de novo M0-M5 AML (Table 4) . Partial remission (PR) was reached in one patient and five patients did not respond (non-R). Two patients died early due to acute respiratory distress syndrome (ARDS) or fungal infection.
Most patients in CR received 1-4 consolidation cycles with id-A or hd-A-based chemotherapy and three underwent autologous stem cell transplantation (ASCT). These three latter patients have been alive in first CR since 21-54 months. All five remaining patients relapsed after 5.0-26.4 months. One of them reached a second CR after id-A þ D reinduction but died due to CNS relapse and sepsis. Another of these patients underwent stem cell transplantation from an unrelated donor (USCT) and reached a second CR but died in relapse. One patient underwent USCT in first PR and died of sepsis 14 days later. The median EFS 7 and OS 7 of 16 patients with de novo AML M0-M5 was 2.5 (0-54 þ ) months and 14.2 (0.1-55 þ ) months, respectively. The median OS in 13 of these patients treated without stem cell transplantation was 9 (0.1-32) months.
Two of the five patients with therapy-related or post-MDS M0-M5 AML received intensive chemotherapy without success. The remaining three received only hydroxyurea or supportive therapy. Survival of these five patients was 0.6-3.0 months, significantly shorter (log-rank test, P ¼ 0.001) than that of de novo NT-AML patients.
Two of the three patients with M6 AML achieved a CR lasting for 2 and 8 months. The third patient did not respond to 
Table 2
Immunophenotypic characteristics of bone marrow blasts of 25 patients with NT-AML Case no. CD13 CD33 CD117 MPO CD15 CD65 CD14 GPA CD41 CD61 CD34 HLA-DR CD7 CD56 CD4 Other T-lin B-lin
Results:+: positive; À: negative. 83-87o4n4,XXXX,del(1)(q11q32),der(1)del(1)(p11p22)(q12qter),À2,À3,der(3)t(3;?)(p11;?),del(5q)(q13q32)x2,À6,À7, del(8q)(q22-q23)x2,i(8)(q10)x2,i(8)(q10),+9,der(9;17)(p10;q10)x2,À11,add (11) 81-83o4n4,XXX,t(X;8)(q22;?),À1,t(1;12)(?;?),À2,der(3)t(1;3)(?;?),der(4)t(X;4)(?;?),der(5)t(5;10)(q11;?)x2,À6,À7, der(7)t(1;7)(?;q11),À9,À9,der(10)t(5;10)(?;?),der(11)t(X;11)(?;p13),der (12) Letters to the Editor treatment. Survival of these three patients was 2.4-10.4 months. The patient with M7 AML reached CR after one cycle of TAD but during the hypoplastic phase severe fungal pneumonia prevented further chemotherapy and he died 8.5 months after diagnosis. This large series describing the clinical and laboratory features of the rare leukemia NT-AML showed that most European patients displayed involvement of at least two myeloid lineages reflected by morphology and immunophenotype. The undifferentiated morphology of NT-blasts observed in the 40% of cases with M0 AML stresses the fact that it may be difficult to establish a proper diagnosis of NT-AML without immunophenotypic examination. Cytogenetic findings displayed at least one abnormality of chromosomes 5, 7, 1, 2, 3, and/or 17. The outcome of these patients was poor after standard chemotherapy 7 but our data suggest that patients with de novo NT-AML might benefit from therapy with intermediate or high doses of cytosine-arabinoside combined with anthracyclines for CR induction and/or consolidation, followed by autologous stem cell transplantation in first CR. Family studies demonstrate that there is an inherited component in a significant proportion of CLL patients. The average age of onset in familial CLL is approximately 10-20 years earlier than in sporadic CLL, suggesting that familial anticipation occurs although this may be due to ascertainment bias. 1, 2 We have previously reported the development of a sensitive flow cytometric assay which can detect as little as a single CLL cell in 10 5 leucocytes without prior knowledge of any immunophe-
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